The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
 
Andreea Varga
No Relationships to Disclose
 
Capucine Baldini
No Relationships to Disclose
 
Patricia Martin-Romano
No Relationships to Disclose
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Inivata (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); OncoMed (Inst); Onxeo (Inst); ose pharma (Inst); ose pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
David Planchard
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD Oncology; Novartis; Pfizer; Roche
 
Stephane Champiat
No Relationships to Disclose
 
ERIC ANGEVIN
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen; SERVIER
 
Rastislav Bahleda
No Relationships to Disclose
 
Anas Gazzah
No Relationships to Disclose
 
Jean-Pierre Armand
No Relationships to Disclose
 
Xavier Paoletti
No Relationships to Disclose
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Oncology; AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; Orion; Pfizer; Roche
 
Jean-Charles Soria
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Honoraria - AstraZeneca; Bristol-Myers Squibb; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Pfizer; Pierre Fabre; Roche; Sanofi
 
Aurelien Marabelle
Honoraria - AMGEN; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Roche/Genentech; Sanofi; SERVIER
Consulting or Advisory Role - AMGEN; Eisai; etherna; GENMAB; GENTICEL; GlaxoSmithKline; Kyowa Hakko Kirin; Lytix Biopharma; Merck Serono; NEKTAR; NOVARTIS; Pfizer; Pierre Fabre; RIGONTEC; Symphony Evolution
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MERUS (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Other Relationship - PEGASCY